Galapagos

Galapagos NV is a biotechnology company, which engages in the identification and development of small molecule and antibody therapies. Its clinical pipeline includes filgotinib, GLP3667, Toledo program, and idiopathic pulmonary fibrosis. The company was founded by Onno van de Stolpe, Rudi Pauwels, and Helmuth van Es on June 30, 1999 and is headquartered in Mechelen, Belgium.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

The company's new salt-inducable kinase inhibitor program is getting off to a rocky start.

Here's Why Galapagos Stock Is Falling Today

Galapagos (GLPG) announces data from multiple studies evaluating its two inflammatory candidates - GLPG3970 and GLPG3667. Stock down.

Galapagos (GLPG) Falls on Inflammatory Study Data Readout

Galapagos NV (NASDAQ: GLPG) reported topline results with tyrosine kinase 2 (TYK2) inhibitor GLPG3667 in a Phase 1b study in psoriasis patients. At Week 4, four out of 10 patients in the high dose group had at least a 50% improvement in severity index (PASI 50) from baseline, compared to one out of 10 subjects on placebo.

Galapagos' Another Psoriasis Candidate Shows Efficacy, Safety Profile In Mid-Stage Study

Galapagos NV (NASDAQ: GLPG) reports topline results from three studies evaluating GLPG3970, a SIK inhibitor, in psoriasis, ulcerative colitis (UC), and rheumatoid arthritis (RA).  26-patient CALOSOMA psoriasis trial.

Galapagos Shares Drop As SIK Inhibitor Fails To Show Positive Outcomes In Ulcerative Colitis, Rheumatoid Arthritis Patients

Mechelen, Belgium; 1 4 July 2021; 2 2 . 01 CET ; regulated information - Galapagos NV (Euronext & Nasda q : GLPG) reports positive topline results with tyrosine kinase 2 ( TYK2 ) inhibitor GLPG3667 in a Phase 1b study in psoriasis patients . GLPG3667 was discovered by Galapagos.

Galapagos reports positive topline results with selective TYK2 inhibitor GLPG3667 in Phase 1b psoriasis study

Mechelen, Belgium; 14 July 2021; 2 2 . 01 CET ; regulated information – Galapagos NV (Euronext & Nasda q : GLPG) reports topline results with GLPG3970 in three pati e nt studies . GLPG3970 , the first product candidate from a broad portfolio of SIK inhibitor compounds, provides clinical data supporting the role of SIK inhibition in inflammation. SIK is a novel target class discovered by Galapagos .

Galapagos demonstrates early clinical activity with SIK2/3 inhibition in inflammation

New post-hoc analys es of data from SELECTION P hase 3 program presented at European Crohn's and Colitis Organisation (ECCO) virtual congress

Galapagos announces new data supporting rapid symptom improvement and sustained steroid-free remission with filgotinib in patients with Ulcerative Colitis

Galapagos has over $6.2 billion in cash with no debt and a market capitalization of only $4.5 billion. The company has an approved product that is expected to generate €500 million annually in sales in Europe in the medium term.

Galapagos: It's Not As Bad As Valued By The Market

Mechelen, Belgium; 22 June 202 1 , 22.01 CET; regulated information – Galapagos NV (Euronext & NASDAQ: GLPG) announces the departure of Dr. Piet Wigerinck later this year .

Galapagos announces departure of CSO Piet Wigerinck later this year

Mechelen, Belgium, 27 May 2021, 22 :01 CET, – Galapagos NV (Euronex t & Nasdaq: GLPG) today announced that 15 abstracts , including scientific updates, and data providing further understanding on the profile of filgotinib as a treatment for people with Rheumatoid Arthritis (RA) , will be presented at the European League Against Rheumatism (EULAR) virtual congress 2021, 2-5 June .

Galapagos to present data on rheumatoid arthritis at the upcoming European League Against Rheumatism (EULAR) congress

Study uses mobile device technology to support capture of patient - reported outcomes during early and ongoing use of stud y treatment amongst patients with rheumatoid arthritis

Galapagos announces first patient enrolled in FILOSOPHY study to advance understanding of Jyseleca (filgotinib) effectiveness and safety in a real-world setting

Galapagos NV (GLPG) CEO Onno van de Stolpe on Q1 2021 Results - Earnings Call Transcript

Galapagos NV (NASDAQ: GLPG) is chopping its pipeline to conserve cash while its business development team pursues a mission to find a “transformative” deal for the company. The company is ditching its Idiopathic pulmonary fibrosis (IPF) molecule '1205 while moving ahead with a Phase 2 IPF study for its chitinase inhibitor '4617.

Galapagos Drops Early Metabolic & Osteoarthritis Programs, Reorganizes R&D Efforts

Gilead Sciences

Application is based on Phase 2b/3 SELECTION study data with patients with moderately to severely active ulcerative colitis

Gilead Sciences submits new drug application in Japan for filgotinib for the treatment of ulcerative colitis with an inadequate response to conventional therapies

Mechelen, Belgium; 08 April 2021; 22.01 CET; Galapagos (Euronext & Nasdaq; GLPG) announced today that Gilead and Galapagos signed an amendment to the share subscription agreement closed in 2019, extending the full lock-up of Gilead's current shareholding in Galapagos to 2024.

Extension of lock-up period in Gilead-Galapagos collaboration agreement

Mechelen, Belgium; 24 March 2021; 21.01 CET; Galapagos (Euronext & Nasdag; GLPG) announced today that its Supervisory Board has promoted Bart Filius to President and Chief Operating Officer (COO). Going forward, CEO Onno van de Stolpe will maintain oversight of the research and development activities, while Bart Filius will take responsibility for business development, commercial strategy, finance, human resources, and other business operations.

Galapagos appoints Bart Filius as President and Chief Operating Officer

Galapagos received a CRL on filgotinib in rheumatoid arthritis.

Galapagos May Finally Get Around Its CRL Situation

New York, New York--(Newsfile Corp. - March 14, 2021) - Pomerantz LLP is investigating claims on behalf of investors of Galapagos NV ("Galapagos" or the "Company") (NASDAQ: GLPG). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980.The investigation concerns whether Galapagos and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. [Click here for information about joining the class...

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Galapagos NV - GLPG

Galapagos NV (NASDAQ: GLPG) has announced interim results from two ongoing safety studies investigating the effect of Jyseleca (filgotinib) on sperm parameters in males with inflammatory bowel disease (MANTA study) or rheumatic conditions (MANTA-RAy study). Out of the 248 randomized patients, 240 reached Week 13 with two evaluable semen samples at baseline and Week 13.

Galapagos' Filgotinib Shows Interim Safety In Ongoing Studies

GALAPAGOS REPORTS PRIMARY ENDPOINT FOR THE ONGOING FILGOTINIB MANTA AND MANTA-RAy SAFETY STUDIES

Despite some serious setbacks, this beaten-down biotech could be a terrific bargain at recent prices.

Is Galapagos Stock a Bad-News Buy Right Now?

Galapagos NV's (GLPG) CEO Onno van de Stolpe on Q4 2020 Results - Earnings Call Transcript

Gilead (GILD) and partner Galapagos announce their decision to discontinue development of ziritaxestat in patients with idiopathic pulmonary fibrosis.

Gilead (GILD) & Galapagos Discontinue Development of IPF Drug

Shares of Gilead Sciences Inc. were down 0.1% in premarket trading on Thursday, the day after the company said an experimental idiopathic pulmonary fibrosis drug it was developing with Galapagos failed a Phase 3 clinical trial. Shares of Galapagos were down 3.5%.

Gilead, Galapagos drug fails in Phase 3 clinical study

Despite solid signs of efficacy in mid-stage trials, the partners are shutting down all clinical trials with ziritaxestat.

News for Galapagos Stock (GLPG)